ArticleArthroplasty today2022
Bisphosphonates in Total Joint Arthroplasty: A Review of Their Use and Complications.
Article in Arthroplasty today, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Denosumab and bone loss in uncemented total hip arthroplasty: a secondary 5-year follow-up of a randomized controlled trial.Acta orthopaedica · 2026Trial
- Revision Risk Following Total Hip Arthroplasty in Patients With Rheumatoid Arthritis: A Cohort Study From the Australian Orthopaedic Association National Joint Replacement Registry.ANZ journal of surgery · 2026Article
- Impact of Preoperative Osteoporotic Medications on Total Hip Arthroplasty Outcomes.Arthroplasty today · 2026Article
- Perioperative denosumab exposure and risk of revision after total hip and knee arthroplasty in osteoarthritis: a registry-based data linkage study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Antiresorptive Therapy and Revision Risk After Primary Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.Arthroplasty today · 2026Article
- Improving Total Joint Outcomes: A Survey of Surgeon Implementation of Perioperative Optimization Protocols.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2025Article
- Abaloparatide effects on BMD in acetabular regions corresponding to DeLee and Charnley zones in women with postmenopausal osteoporosis.Bone reports · 2025Article
- The growing burden of periprosthetic fractures after total hip arthroplasty: identifying overall trends and at-risk groups.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Article
- Pharmacological Intervention with 4-Phenylbutyrate Ameliorates TiAl6V4 Nanoparticles-Induced Inflammatory Osteolysis by Promoting Macrophage Apoptosis.Bioengineering (Basel, Switzerland) · 2025Article
- Does Preoperative Bisphosphonate Use Impact the Risk of Periprosthetic Fracture Following Total Hip Arthroplasty?The Journal of arthroplasty · 2025Article
- Cementless fixation in total joint arthroplasty: Factors impacting osseointegration.Journal of clinical orthopaedics and trauma · 2025Review
- Periprosthetic fractures are osteoporotic fractures: missed opportunities for osteoporosis diagnosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Article
- Osteoarthritis: Insights into Diagnosis, Pathophysiology, Therapeutic Avenues, and the Potential of Natural Extracts.Current issues in molecular biology · 2024Review
- Rehabilitation: Neurogenic Bone Loss after Spinal Cord Injury.Biomedicines · 2023Review
- Advanced Procedure of Simultaneous Electrodeposition from a Natural Deep Eutectic Solvent of a Drug and a Polymer Used to Improve TiZr Alloy Behavior.Materials (Basel, Switzerland) · 2023Article
- Hormone replacement therapy does not increase thrombosis risk following THA: a national database study.Journal of experimental orthopaedics · 2023Article
- Periprosthetic fractures: an unrecognized osteoporosis crisis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023Article
- The histological assessment of new bone formation with zolendronic acid loaded bone allograft in rabbit femoral bone defect.Journal of medicine and life · 2023Article
- Recent Advancements in Metallic Drug-Eluting Implants.Pharmaceutics · 2023Review
- The Role of the Innate Immune System in Wear Debris-Induced Inflammatory Peri-Implant Osteolysis in Total Joint Arthroplasty.Bioengineering (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Considerable interest has been expressed in the use of bisphosphonates to treat periprosthetic osteoporosis with the clinical goals of reducing periprosthetic fractures and prolonging implant survival. Methods: A systematic review was performed with the goal of identifying both basic science and clinical studies related to the risks and benefits of bisphosphonate use in total joint arthroplasty. Results: Studies have shown that bisphosphonates may increase early bony ingrowth, decrease the postoperative loss of bone mineral density, and increase the longevity of implants by reducing the need for revisions secondary to aseptic loosening. Continuing bisphosphonates for 1 year postoperatively seems to provide the greatest benefit, with only marginal benefit being shown by continuing therapy for up to 2 years. Current data present some concerns for an increased risk of periprosthetic fractures especially in younger patients, and prolonged therapy is not recommended due to the potential risk of atypical femur fractures. Patients should be counseled regarding the risk of side effects of bisphosphonates, including the risk of osteonecrosis of the jaw, which is a rare but serious side effect. They should also be counseled on the risk of atypical femur fractures and gastrointestinal intolerance. Conclusions: Orthopedic surgeons could consider bisphosphonates for up to 1 year postoperatively regardless of the patient's prior bone mineral density, after discussion regarding the risks and benefits with the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.